Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170624 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAMAPK1CFTRSLC6A2 | |
| SCHEMBL2684159 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAMAPK1CFTRSLC6A2 | |
| SCHEMBL31404936 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAMAPK1CFTRSLC6A2 | |
| Sulfuric Acid SCHEMBL6228059 | 0.93 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAMAPK1CFTRSLC6A2 | |
| Mandelic Acid SCHEMBL810372 | 0.83 | ALDH1A1 (0.68) | SMN1; SMN2LMNAMAPK1GAAALDH1A1 | |
| SCHEMBL3135737 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNACFTRSLC6A2SLC6A4 | |
| SCHEMBL14828702 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNACFTRSLC6A2SLC6A4 | |
| SCHEMBL28049857 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNACFTRSLC6A2SLC6A4 | |
| SCHEMBL29658816 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNACFTRSLC6A2SLC6A4 | |
| SCHEMBL3103512 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNACFTRSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0000560-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE ALPHA-HYDROXYCARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-02-03 | — | — | EP | claimed |
| US-4204044-A | SELECTIVE ASYMMETRIC, ENZYMATIC DEHYDROGENATIKN USING STREPTOMYCES, PSEUDOMONAS, BACILLUS OR CORYNEFORM MICROORGANISMS | HOFFMANN-LA ROCHE INC. (US) | 1980-05-20 | — | — | US | claimed |
| JP-8205878-A | — | — | None | — | — | JP | disclosed |
| US-12122778-B2 | Activating pyruvate kinase R | NOVO NORDISK HEALTH CARE AG (CH) | 2024-10-22 | — | — | US | disclosed |
| EP-3852791-B1 | ACTIVATING PYRUVATE KINASE R | NOVO NORDISK HEALTHCARE AG (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-4303216-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-01-10 | — | — | EP | disclosed |
| CN-116981661-A | Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-20230055923-A1 | ACTIVATING PYRUVATE KINASE R | NOVO NORDISK HEALTH CARE AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230055923-A1 | ACTIVATING PYRUVATE KINASE R | NOVO NORDISK HEALTH CARE AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-5519132-A | ALZHEIMER*S DISEASE, NERVOUS SYSTEM DISORDERS, PROMOTE RELEASE OF ACETYLCHOLINE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-21 | — | — | US | disclosed |
| US-5428035-A | Enhance the release of neurotransmitter acetylcholine and useful for treating alzheimer's disease and cognition activator | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-27 | — | — | US | disclosed |
| WO-1994007891-A1 | 1-SUBSTITUTED OXINDOLES AND AZAOXINDOLES AS NOVEL COGNITION ENHANCERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-04-14 | — | — | WO | disclosed |
| US-5296478-A | 1-substituted oxindoles as cognition enhancers | THE DUPONT MERCK PHARMACEUTICAL CO. (US) | 1994-03-22 | — | — | US | disclosed |
| US-4606756-A | Herbicidal 2-(nitrogen heterocycle)5-amino-3-oxo-4-(substituted-phenyl)-2,3-dihydrofurans | CHEVRON RESEARCH COMPANY (US) | 1986-08-19 | — | — | US | disclosed |
| EP-0053408-B1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED GLYOXYLIC ACID DERIVATIVES | STAMICARBON B.V. (NL) | 1984-10-17 | — | — | EP | disclosed |
| US-4417053-A | Process for the preparation of substituted glyoxylic acid derivatives | STAMICARBON B.V. (NL) | 1983-11-22 | — | — | US | disclosed |
| EP-0053408-A1 | Process for the preparation of substituted glyoxylic acid derivatives | STAMICARBON B.V. (NL) | 1982-06-09 | — | — | EP | disclosed |
| US-4204044-A | SELECTIVE ASYMMETRIC, ENZYMATIC DEHYDROGENATIKN USING STREPTOMYCES, PSEUDOMONAS, BACILLUS OR CORYNEFORM MICROORGANISMS | HOFFMANN-LA ROCHE INC. (US) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055923-A1 | ACTIVATING PYRUVATE KINASE R | PDK1, PDK2, PKLR | SMN1; SMN2 1423/4885LMNA 2040/4885MAPK1 762/4885 |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, HASPIN | SMN1; SMN2 4568/4885LMNA 1934/4885MAPK1 300/4885 |
| US-12122778-B2 | Activating pyruvate kinase R | PDK1, PDK2, PKLR | SMN1; SMN2 1423/4885LMNA 2040/4885MAPK1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.